Year: 2021

  DASSAULT AVIATION   French corporation (société anonyme) with a share capital of 66,789,624 euros Headquarters: 9, Rond-Point des Champs-Elysées Marcel Dassault – 75008 PARIS RCS PARIS 712 042 456     Information concerning the total number of voting rights and shares as per article L. 233-8 II of the French Commercial Code (Code de commerce) and article 223-16 of the General Regulations (Règlement Général) of the French Market Authority (Autorité des Marchés Financiers)        DateTotal number of sharesTotal number of voting rights10/29/2021 83,487,030Theoretical voting rights: 135,537,031 Exercisable voting rights: 135,226,901   AttachmentTotal number of shares and voting rights – 29 10 21

8 November 2021Net Zero by 2040 ICG makes global commitment to reach net zero by 2040 2030 emissions reduction targets covering 100% of relevant investments1approved by the Science Based Targets initiative Intermediate Capital Group plc (“ICG” or the “Group”), the global alternative asset manager with $65bn assets under management, announces today its commitment to reach net zero greenhouse gas (GHG) emissions across its operations and investments by 2040. The Group’s net zero commitment is supported by two ambitious emissions reduction targets by 2030, which have been approved and validated by the Science Based Targets initiative (SBTi). Approved and validated science-based targets:Ensure 100% of relevant investments have SBTi-approved science-based targets by 2030, with an interim target of 50% by 20261 Reduce ICG’s direct (Scope...

First dry-powder formulation of treprostinil to meet criteria required for FDA approval Final FDA approval may occur in October 2022 or earlier upon resolution of on-going litigation Conference call and webcast scheduled for today at 9:00 a.m. Eastern Standard TimeMORRISVILLE, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861. YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. Tentative approval indicates that YUTREPIA has met all regulatory standards for quality, safety and efficacy...

Oslo (Norway), 8 November 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the coordinating principal investigator for the RELEASE trial, Prof. Dr. Jörg Trojan, Head of Gastrointestinal Oncology Unit, Goethe University Hospital, Frankfurt, Germany will present results from the fimaChem Phase I study in bile duct cancer and the design and status of the ongoing pivotal RELEASE study at the online event ‘Light-responsive platforms for controlled drug delivery’ hosted by IPA (International Photodynamic Association). The online event is scheduled for 15:30-18:00 CET today and the presentation by Prof. Trojan is named ‘PCI of gemcitabine in locally advanced inoperable cholangiocarcinoma – a new technique with promising clinical activity’. Please find the presentation enclosed. The event also includes...

BEIJING, Nov. 08, 2021 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has entered into a strategic partnership with NeoGenomics, Inc. (NASDAQ: NEO), a company that specializes in cancer genetic testing and information services. Genetron Health and NeoGenomics, Inc. will partner globally to provide select harmonized clinical trials, global translational research for pharmaceutical groups and technology platform providers that need a China arm for global or China focused trials. Additionally, NeoGenomics will support Genetron Health on ex-China trials requiring US, APJ and/or EMEA...

Miami, FL, Nov. 08, 2021 (GLOBE NEWSWIRE) — Blue Star Foods Corp., (NASDAQ:BSFC) (“Blue Star” or “BSFC”), an integrated Environmental, Social, and Governance (ESG) seafood company, today announced that its wholly owned Recirculatory Aquaculture Systems (RAS) subsidiary, Taste of BC Aquafarms (“TBC”), has identified Deep Bay, British Columbia as the location for its planned larger-scale land-based steel-head salmon farm. TBC has also agreed upon material terms of a 20-year land-lease agreement for the Deep Bay property. The land-lease agreement will be for a property of approximately 20 acres, with an option to expand onto an additional 10 acres. The property is within a designated Agricultural Land Reserve within the Regional District of Nanaimo which supports commercial aquaculture without additional re-zoning. The site sits upon...